Determinantes de la probabilidad de padecer enfermedades inflamatorias intestinales

Simple item page
dc.creatorVásquez, Harold
dc.creatorVásquez, Howard
dc.date2017-07-01
dc.date.accessioned2020-09-10T20:17:13Z
dc.date.available2020-09-10T20:17:13Z
dc.descriptionBased on a universe of 116 patients, we conducted a cross-sectional and prospective data collection descriptive observational study to determine the effectiveness of fecal calprotectin in known and highly suspected inflammatory bowel disease patients. Unlike previous studies, we use a series of econometric to estimate the probability that a patient suffering from ulcerative colitis or Crohn's disease (CU-EC) given the level of calprotectin detected in the stool models. The results indicate that this probability may differ in significant quantities depending on sex, age and habits of the patient. For example, in the case of men, the likelihood of developing CU-EC is significantly higher than for women, even at low levels of fecal calprotectin. In addition, the odds ratio of developing CU-EC increased until the patient reaches age 37, age at which the chance of developing inflammatory bowel disease begins to gradually decline. Finally, the probability that a patient has UC-EC is higher for people who say they smoke to snuff, even though this result seems not be significant in statistical terms.en-US
dc.descriptionEn base a un universo de 116 pacientes, realizamos un estudio observacional descriptivo transversal y de recolección de datos prospectivo con el fin de determinar la eficacia de la calprotectina fecal en pacientes conocidos y con alta sospecha de enfermedad inflamatoria del intestino. A diferencia de estudios anteriores, utilizamos una serie de modelos econométricos para estimar la probabilidad de que un paciente padezca Colitis Ulcerativa o Enfermedad del Crohn  (CU-EC) dado el nivel de calprotectina detectado en las heces fecales. Los resultados indican que esta probabilidad puede diferir en magnitudes significativas dependiendo del sexo, la edad y los hábitos de consumo del paciente. Por ejemplo, en el caso de los hombres, la probabilidad de padecer CU-EC es significativamente mayor que para las mujeres, incluso en niveles bajos de calprotectina fecal. Además, la razón de probabilidades de padecer CU-EC aumenta hasta que el paciente alcanza los 37 años, edad en que la probabilidad de contraer una enfermedad inflamatoria intestinal comienza a reducirse paulatinamente. Finalmente, la probabilidad de que un paciente padezca CUEC es mayor para las personas que declaran ser fumadoras de tabaco, a pesar de que este último resultado no aparenta ser significativo en términos estadísticos.es-ES
dc.formatapplication/pdf
dc.formattext/html
dc.identifierhttps://revistas.intec.edu.do/index.php/ciene/article/view/1109
dc.identifier10.22206/ceyn.2017.v1i1.pp157-185
dc.identifier.urihttps://repositoriobiblioteca.intec.edu.do/handle/123456789/2790
dc.languagespa
dc.publisherInstituto Tecnológico de Santo Domingo (INTEC)es-ES
dc.relationhttps://revistas.intec.edu.do/index.php/ciene/article/view/1109/pdf_vasquez
dc.relationhttps://revistas.intec.edu.do/index.php/ciene/article/view/1109/html_HaroldVasquez
dc.relation/*ref*/Fagerhol MK, Dale I, y Andersson T. 1980. “A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells.” Bull Eur Physiopathol Respir; 16 Suppl: 273-282.
dc.relation/*ref*/Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, y Dale I. 1997. “Functional and clinical aspects of the myelomonocyte protein calprotectin.” Mol Pathol; 50: 113123.
dc.relation/*ref*/Kallel L, Ayadi I, Matri S, Fekih M, Mahmoud NB, y Feki M. 2010. “Fecal calprotectin is a predictive marker of relapse in Crohn’s disease involving the colon: a prospective study.” Eur J Gastroenterol Hepatol; 22(3): 340–5.
dc.relation/*ref*/Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G. 2012. “Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.” Gastroenterology; 42(1): 46-54.e42; enero 2012.
dc.relation/*ref*/Nicholas A. Kennedy, Annalie Clark, y Andrew Walkden. 2014. “Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16–50 years”. J Crohns Colitis; 9(1): 41–49. January 2012.
dc.relation/*ref*/Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, y Bruegger LE. 2010. “Fecal calprotectina correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES CD) than CRP, blood leukocytes, and the CDAI.” Am J Gastroenterol;105(1):162–9.
dc.relation/*ref*/Sipponen T y Kolho KL. 2010. “Faecal calprotectin in children with clinically inflammatory bowel disease.” Scand J Gastroenterol; 45(7 8): 872–7.
dc.relation/*ref*/Van Rheenen PF, Van de Vijver E y Fidler V. 2010. “Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta analysis.” British Medical Journal; 341: c3369.
dc.rightsDerechos de autor 2017 Ciencia, Economía y Negocioses-ES
dc.sourceScience, Economy & Business; Vol 1 No 1 (2017): Science, Economics and Business; 157-185en-US
dc.sourceCiencia, Economía y Negocios; Vol. 1 Núm. 1 (2017): Ciencia, Economía y Negocios; 157-185es-ES
dc.source2613-8778
dc.source2613-876X
dc.source10.22206/ceyn.2017.v1i1
dc.subjectcalprotectinen-US
dc.subjectulcerative colitisen-US
dc.subjectCrohn’s diseaseen-US
dc.subjectProbiten-US
dc.subjectLogit modelsen-US
dc.subjectJEL Codesen-US
dc.subjectI10en-US
dc.subjectI12en-US
dc.subjectC25en-US
dc.subjectcalprotectinaes-ES
dc.subjectcolitis ulcerativaes-ES
dc.subjectenfermedad Crohnes-ES
dc.subjectProbites-ES
dc.subjectLogites-ES
dc.subjectCódigos JELes-ES
dc.subjectI10es-ES
dc.subjectI12es-ES
dc.subjectC25es-ES
dc.titleDeterminants of probability of suffering inflammatory bowel diseasesen-US
dc.titleDeterminantes de la probabilidad de padecer enfermedades inflamatorias intestinaleses-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
Files
Collections
Artículos EN